Injectable naltrexone can be an effective treatment for opioid use disorder, but it requires complete abstinence before initiation—a process that can take more than a week and cause significant discomfort. Here, researchers evaluate a new protocol designed to accelerate this induction period and improve patient access.
Xylazine is a non-opioid sedative commonly added surreptitiously to illicit opioids. One particularly challenging adverse effect of xylazine exposure is the development of peripheral wounds, some of which can be severe, necessitating surgical intervention and even amputation. In this interview, Dr. D’Orazio teaches us how these wounds might be caused, how to discuss them with your patients, and the best treatment approach.
Substance use is associated with many dental problems, some of which can even be life threatening. Here, Dr. Ouanounou discusses which specific dental issues addiction treatment providers need to be on the lookout for. He covers the basics of dental examination and teaches us when referral to specialty care is warranted.
.png?1740598238)
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
